A world without neurodegenerative diseases.

Neurodegeneration is characterized by progressive loss of structure or function of neurons that lead to varying degrees of dementia or memory loss. Alzheimer's disease accounts for two-thirds of all dementia affecting over 40 million people worldwide.  There is an urgent need for vibrant drug discovery initiatives to produce efficacious therapeutic leads.  

Alzheimer's disease

Adult human brain has approximately 100 billion neurons that exhibit long, branching extensions that enable connections or synapses between two neurons. Information transmission occurs as tiny bursts of chemicals released through the synapses and forms the basis for memories, thoughts, sensations, and emotions. In Alzheimer's disease, inflammatory mediators and abnormal accumulations of proteins in the brain cause damage and destruction of neurons. This interferes with neuron-neuron communications at synapses leading to memory loss and other symptoms.

         Disease Modifying Drug: Biomolecules

Protein-protein interactions are used as targets. Design and development of small molecule and peptide inhibitors are directed to combatting or preventing neurodegeneration.